A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability of GC1118 in combination
with irinotecan or FOLFIRI in order to determine the maximum tolerated dose (MTD) and the
recommended phase 2 dose (RP2D)